BridgeBio Pharma, Inc.
BBIO
$61.37
-$0.61-0.98%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -797.12M | -776.42M | -667.97M | -535.76M | -438.86M |
| Total Depreciation and Amortization | 5.37M | 5.51M | 5.76M | 6.08M | 6.29M |
| Total Amortization of Deferred Charges | 4.52M | 5.40M | 5.40M | 5.40M | 5.40M |
| Total Other Non-Cash Items | 290.15M | 195.64M | 15.31M | -28.48M | -64.13M |
| Change in Net Operating Assets | -87.73M | -85.94M | 141.08M | 32.04M | 41.08M |
| Cash from Operations | -584.82M | -655.81M | -500.42M | -520.73M | -450.22M |
| Capital Expenditure | -1.11M | -778.00K | -238.00K | -933.00K | -1.32M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 0.00 | -42.00K | -140.00K | -140.00K | -140.00K |
| Other Investing Activities | -12.26M | 21.21M | 36.81M | 61.85M | 65.41M |
| Cash from Investing | -13.37M | 20.39M | 36.43M | 60.78M | 63.95M |
| Total Debt Issued | 1.38B | 1.38B | 1.08B | 950.00M | 450.00M |
| Total Debt Repaid | -459.00M | -459.00M | -459.00M | -473.42M | -473.42M |
| Issuance of Common Stock | 23.79M | 17.92M | 10.76M | 323.15M | 320.64M |
| Repurchase of Common Stock | -56.48M | -54.89M | -54.90M | -7.78M | -8.93M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -47.90M | -42.01M | -42.62M | -43.50M | -18.29M |
| Cash from Financing | 835.41M | 837.01M | 529.24M | 748.46M | 270.00M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 237.22M | 201.59M | 65.25M | 288.51M | -116.26M |